U.S. stocks steady; Cook’s dismissal, Nvidia earnings in spotlight
PASADENA, CA— Xencor Inc (NASDAQ:XNCR) Director Kurt A. Gustafson sold 2,993 shares of the company’s common stock on June 16, 2025, at an average price of $9.22 per share, totaling $27,595. The sale comes as Xencor’s stock trades near its 52-week low of $7.16, having declined over 63% in the past six months. This transaction was conducted under a 10b5-1 plan adopted by Gustafson on June 28, 2024.
Earlier in the month, on June 12, Gustafson acquired 13,686 shares of common stock, which were restricted stock units set to fully vest on the first anniversary of the grant date. Additionally, he obtained 27,372 stock options on the same day, with the right to buy at an exercise price of $9.43 per share. These options will vest in equal monthly installments over the coming year, reaching full vesting by June 12, 2026. According to InvestingPro, Xencor maintains strong liquidity with a current ratio of 5.89, though analysts have recently revised earnings expectations downward.
Following these transactions, Gustafson’s direct ownership in Xencor stands at 20,183 shares of common stock. With analyst price targets ranging from $6 to $40, InvestingPro analysis reveals 8 additional key insights about Xencor’s financial health and market position in their comprehensive Pro Research Report.
In other recent news, Xencor, Inc. has announced the advancement of its investigational anti-TL1A antibody, XmAb942, into a Phase 2b study for patients with moderate-to-severe ulcerative colitis, following positive interim results from a dose-escalation study. The study, set to begin in the second half of 2025, will evaluate the drug’s efficacy and safety in patients who have not responded to other therapies. Additionally, Xencor is progressing with its XmAb TL1A x IL23p19 bispecific antibody program, aiming for a first-in-human study in 2026. Meanwhile, JPMorgan has adjusted its price target for Xencor to $20 from $23, maintaining an Overweight rating, highlighting the company’s focus on immunological research and strategic execution. The first quarter results for Xencor met expectations, with no major surprises reported. William Blair has initiated coverage on Xencor with an Outperform rating, citing the potential of Xencor’s pipeline to produce distinctive clinical data in the next 6 to 12 months. This positive outlook is based on the company’s advancements in T-cell engagers for cancer treatment, supported by its XmAb platform. These developments underscore Xencor’s ongoing efforts and potential impact in the biopharmaceutical field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.